GH Research (NASDAQ:GHRS) Shares Up 2.8% – Time to Buy?

GH Research PLC (NASDAQ:GHRS)’s share price traded up 2.8% on Wednesday . The company traded as high as $8.33 and last traded at $8.33. 3,888 shares changed hands during trading, a decline of 95% from the average session volume of 79,718 shares. The stock had previously closed at $8.10.

Analyst Ratings Changes

Several equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th. JMP Securities restated a “market outperform” rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.

GH Research Stock Performance

The stock has a market cap of $452.14 million, a PE ratio of -12.36 and a beta of 0.79. The stock has a fifty day simple moving average of $8.09 and a two-hundred day simple moving average of $10.55.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. On average, equities analysts predict that GH Research PLC will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,251,714 shares of the company’s stock after acquiring an additional 664,381 shares during the quarter. RA Capital Management L.P. owned approximately 12.02% of GH Research worth $66,643,000 at the end of the most recent quarter. Institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).